Programme Thesis
This programme provides non-dilutive grants (€30K–€2.5M) to early-stage startups developing innovative health technologies, aiming to accelerate EU-based ventures that address unmet medical needs and strengthen Europe's competitive edge in MedTech and biopharma. It exists to bridge the funding gap for pre-commercial innovations that have strong scientific validation but lack the resources to scale within the EU ecosystem.
Selection Criteria
- Innovation and technological novelty (e.g., AI-first approach to drug resistance prediction without crystal structure)
- Scientific/technical feasibility and proof-of-concept validation (e.g., AUROC 0.634 on Platinum benchmark, 100% mutation coverage)
- Market potential and alignment with EU health priorities (e.g., oncology, AMR, antiviral resistance)
- Team expertise and track record (founder's dual background as pharmacist + ML engineer)
- Clarity of project plan, milestones, and budget (e.g., roadmap to AUROC ≥0.70, Servier pilot, ARR)
- Potential for collaboration with EU research/industry partners (e.g., Servier, Paris-Saclay, Sanofi)
- Scalability and long-term impact on EU healthcare systems
Past Winners / Cohort Profiles
Typical winners are pre-seed/seed-stage health-tech startups with a validated prototype, strong IP potential, and a clear EU go-to-market plan. Examples include AI-driven diagnostics platforms, digital therapeutics, and computational drug discovery tools. Named examples are not available from the programme page, but archetypes include spin-offs from EU research institutes (e.g., Institut Pasteur) and solo founders with deep domain expertise.
Ideal Candidate Fingerprint
A pre-seed startup with a novel, AI-powered health technology that has demonstrated proof-of-concept (e.g., benchmark results), a clear path to clinical or commercial validation, and strong ties to EU research hubs. The founder should have a compelling personal narrative (e.g., pharmacist-turned-ML engineer) and a realistic plan to incorporate in the EU within the grant period.
Recommended Framing
Eniola should position the venture as a paradigm shift in drug resistance prediction: using protein language models to achieve 100% mutation coverage (vs. 17.6% for structure-dependent tools), directly addressing EU health priorities in oncology and AMR. Emphasize the proof-of-concept AUROC 0.634 on Platinum, the planned fine-tuning on SKEMPI to reach SOTA (≥0.70), and the existing partnership pipeline with Servier, Paris-Saclay, and Sanofi as evidence of EU ecosystem integration. Highlight the founder's unique pharmacist+ML background as a credibility bridge between biology and AI.
Watch Out
The venture is not yet incorporated, which may conflict with eligibility requiring a legal entity in the EU. The AUROC of 0.634 is below the published SOTA (0.70), so the roadmap to improvement must be convincing. The programme's global eligibility may attract strong competition from more mature startups. The lack of page content means specific eligibility details (e.g., incorporation requirement, TRL level) are unknown and must be verified.